Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0009324 (ulcerative colitis)
 17,300 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In 36 unselected patients with ulcerative colitis or Crohn's disease taking 4.5-6 gm. salicylazosulfapyridine per day the incidence of hemolysis and its relation to the serum level of salicylazosulfapyridine (Salazopyrin, Azulfidline, SASP), free sulfapyridine (SP) and acetyl sulfapyridine (ac-SP) was investigated. In 19 patients hemolysis was present. Serum levels of free SP were significantly higher in these patients (P less than 0.001). All patients with a serum SP level higher than 37 microgram./ml. had hemolysis as compared to only four of 21 patients with a serum SP level below 37 microgram./ml. Four patients had evidence of hemolytic anemia. In these patients the serum SP level was higher than 55 microgram./ml. Eighteen of the 19 patients with hemolysis were slow acetylators while six of the 17 patients without hemolysis belonged to the slow acetylator phenotype.
 ...
PMID:Hemolysis during salicylazosulfapyridine therapy. 3 52

Sulphasalazine (SASP) is an immunomodulatory compound with disease-modifying activity in ulcerative colitis and in other autoimmune disorders. SASP was previously shown to prolong the survival of heart allografts in rats treated with cyclosporin A (CyA) for 9 days after transplantation. We have now evaluated whether SASP also exerts a beneficial effect under continuous treatment with CyA, when CyA is discontinued after 14 days, or alone if given 10 days prior to transplantation. Cardiac grafts were transplanted from PVG donors to Wistar/Kyoto recipients using an accessory cervical heart transplantation technique. Rejection was defined as the absence of palpable contractions and occurred in the control group in a very reproducible manner on day 8 or 9. SASP alone was given orally (100 mg/kg body weight) starting 10 days before transplantation and resulted in a minor prolongation of graft survival. When SASP was given in addition to oral CyA (1 mg/kg or 2 mg/kg from day 0 to rejection) there was a significant prolongation in graft survival [from medians of 8 (range 6-11) and 9 (range 8-11) days, respectively, to medians of 10 (range 8-15) and 12 (range 11-15) days, respectively]. When SASP was given from day 0 to rejection, in addition to a schedule of oral CyA (10 mg/kg) for 15 days, there was no prolongation of graft survival [median of 30 (range 26-42) days vs median of 32 (26-38) days]. The data show that SASP acts as a weak immunosuppressive agent which enhances the effect of CyA given at a low dose.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Enhancement of the effect of low-dose cyclosporin A by sulphasalazine in prevention of cardiac allograft rejection in the rat. 135 39

5-Aminosalicylic acid (5-ASA), the active moiety of sulphasalazine (SASP), was given as a rectal enema to patients with mild to moderate distal ulcerative colitis to determine the minimum effective dosage. A double blind study was carried out using enemas containing 1, 2, or 4 g or 5-ASA or placebo for a one month treatment period. One hundred and thirteen patients with ulcerative colitis attending our outpatient clinic volunteered to participate. Clinical, sigmoidoscopic, and histological assessments were carried out at the beginning of the study and after 15 and 30 days of treatment. All patients who received 5-ASA enemas showed significantly better results than those who received a placebo enema (p less than 0.001) but no difference was detected among the patients receiving differing concentrations of 5-ASA. This study suggests that 1 g 5-ASA (in a 100 ml enema) is a sufficient dosage for patients with a mild to moderate attack of ulcerative colitis.
 ...
PMID:Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. 188 75

Sulphasalazine (SASP) is the drug of choice in the treatment of ulcerative colitis (UC). But there are adverse effects in 20-30% dependent on the serum-level of the resorbed SASP-metabolite sulphapyridine (SP). Relapses during treatment may have their cause in an under-dosage or patient's non-compliance. In 19 patients with UC the possibility of an individualized most effective treatment and the patient's compliance by the simple practicable analysis of SP-serum-level were checked. The results show that it is necessary to dose the SASP in dependence of the genetically determined type of acetylation. The SASP-dosage must be decreased in patients with slow acetylation and vice versa consequently. After rectal SASP-application - in opposite to the oral treatment - significant lower serum levels of SP were analyzed. In 63.1% of the patients we found an insufficient of non-compliance.
 ...
PMID:[Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration]. 197 Apr 78

The aim of the study was to compare the efficacy and side-effects of 5-ASA and SASP in the treatment of active ulcerative colitis. An improvement was seen in 71.4% (5-ASA) and 70.3% (SASP) but there were no complete remissions. The incidence of improvements was only 36.3% (5-ASA) and 37.5% (SASP) in pancolitis. The side-effects appeared in 14.2% (5-ASA) and 21% (SASP).
 ...
PMID:[Efficacy and tolerability of 5-aminosalicylic acid in the short-term treatment of ulcerative rectocolitis during the mild or moderate stage]. 197 Aug 55

Salicylazosulfapyridine, commonly known as sulfasalazine or SASP, is an anti-inflammatory drug that is widely used in the treatment of diseases such as ulcerative colitis and Crohn's disease. Increases in sister chromatid exchanges (SCE) and micronuclei (MN) frequencies have been reported in lymphocytes of patients maintained on SASP therapy for up to 21 months. We have tested SASP for its ability to induce chromosome aberrations (ABS) and SCE in cultured Chinese hamster ovary (CHO) cells, ABS in mouse bone marrow cells, and MN in erythrocytes from both bone marrow and peripheral blood of mice. In vitro assays for ABS and SCE were negative. In vivo, SASP administered by single gavage at doses up to 1000 mg/kg did not increase ABS in bone marrow cells of male B6C3F1 mice; however, increases in MN were observed in the peripheral blood erythrocytes of male and female B6C3F1 mice administered 675, 1350 or 2700 mg/kg SASP by gavage for 90 days. Weak but significant dose-related increases in MN were also observed in the bone marrow cells of male B6C3F1 mice administered 500, 1000 and 2000 mg/kg SASP for 3 days. These positive findings in mice support the role of SASP in the induction of MN and SCE in humans, and suggest the need for further evaluation of possible adverse human health effects associated with SASP therapy.
 ...
PMID:Evaluation of the mutagenicity of the anti-inflammatory drug salicylazosulfapyridine (SASP). 197 33

In this paper, the ulcerative colitis model of rats with immuno-method was reported and the mechanism of using Jianpiling for the treatment of ulcerative colitis was studied. The rats of experimental group were subdivided into 3 subgroups (A, B and C), 15% Jianpiling suspension was given to rats in subgroup A per os, 15% Bupi-Yichang Pill to rats in subgroup B per os, 4.5% SASP suspension to rats in subgroup C, and same amount of saline to rats in the control group. The therapeutic results showed that the anti-diarrhia, anti-infection and repairing function of tissue by Jianpiling were obviously better than those of Bupi-Yichang Pill and SASP. Serological exams also showed that Jianpiling was much better than other therapeutic groups in increasing nonspecific cellular immunity and lowering level of antibody against large intestine and IgG. These results suggested that the mechanism of Jianpiling on ulcerative colitis was realized by increasing cellular immunity, inhibiting humoral immunity and promoting immune modulation.
 ...
PMID:[Duplication of animal model of ulcerative colitis and studies on rehabilitation effect of jianpiling prescription]. 220 38

The etiopathogenesis of ulcerative colitis (UC) is still largely unknown, although the role of genetic influences now seems to be fairly clear. Diagnosis is based on clinical, endoscopic and histological findings. The most important differential diagnosis of UC is Crohn's disease (CD). UC always first arises in the rectum and can spread continuously to upper parts of the colon. One of the severest complications consists in the development of toxic megacolon, which is seen in 1.6%-8% of cases. Another point is the occurrence of carcinoma in longstanding and extensive UC. The risk of this complication may have been overestimated in earlier studies: A realistic rate could be 0.5%-1% per person and year of pancolitis. However, carcinoma may occur even in less extensive cases. The conclusions which have to be drawn are still controversial. Some authors recommended regular endoscopy with serial biopsies, but others do not. The standard oral therapy is based on sulfasalazine (SASP) and corticosteroids. For topical treatment, 5(4)-amino-salicylic acid has proven to be effective in distal colitis, as has cortisone. Also, oral treatment with 5-ASA preparations seems to be beneficial, even if some of the published studies are open to criticism. Presumably, the drug is more clearly effective at higher doses than those commonly used.
 ...
PMID:Pathogenesis and management of ulcerative colitis. 268 Aug 57

The effects of sulfasalazine (SASP) and its cleavage products 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP) on prostanoid (PG) synthesis and degradation were determined in rabbit colonic mucosa fractions in vitro. When the microsomal fraction was incubated with (14C)arachidonic acid, 10(-3) M SASP and SP did not markedly change the formation of labeled PGE2, PGF2 alpha, TxB2 and 6-keto-PGF1 alpha X 10(-4) M 5-ASA increased synthesis about 2.7-fold; the pattern of PG identified was unaltered. In the presence of the 10-fold higher concentration of 5-ASA, PG synthesis remained elevated at a similar level. When the cytosolic fraction was incubated with (3H)PGE2, 10(-3) M 5-ASA was without influence and 10(-3) M SP decreased slightly PGE2 breakdown. However, SASP showed a pronounced inhibitory effect at 10(-5) M and inhibition of PGE2 degradation was complete at 10(-3) M SASP. The results are compatible with the assumption that stimulation of PG synthesis by 5-ASA is related to therapeutic benefit in the treatment of ulcerative colitis.
 ...
PMID:Influence of sulfasalazine, 5-aminosalicylic acid and sulfapyridine on prostanoid synthesis and metabolism in rabbit colonic mucosa. 285 16

5-Aminosalicylic acid (5-ASA) suppressed nitrite-stimulated oxidation of the fatty acid n-butyrate in a dose-dependent manner in isolated human and rat colonic epithelial cells. 4-ASA had one-sixth of the capacity of 5-ASA and sulphapyridine (SP) little of the capacity of 5-ASA to suppress fatty acid oxidation in human colonic epithelial cells. Sulphasalazine (SASP), azodisalicylic acid (ADS), acetyl-5-ASA and acetyl salicylic acid (ASA) did not suppress fatty acid oxidation in rat colonocytes. The suppression index of fatty acid oxidation (SIFO) of respective salicylic acids correlated with the reported clinical effectiveness of each drug against ulcerative colitis (UC). The capacity of 5-ASA to affect nitrite-stimulated oxidation of fat in the colonic mucosa suggests that nitrite ions and control of fatty acid oxidation play a central role in the development and therapy of active UC.
 ...
PMID:Effect of 5-aminosalicylic acid (5-ASA) and other salicylates on short-chain fat metabolism in the colonic mucosa. Pharmacological implications for ulcerative colitis. 286 67


1 2 3 4 5 6 Next >>